Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age:10-18 years old~* Liver biopsy proven NAFLD. NAFLD defined histologically as greater than 5% hepatic macrovesicular steatosis with any degree of chronic inflammation and hepatic fibrosis; clinical definition requires that other liver diseases associated with fatty liver be excluded.~* Insulin resistance with HOMA-IR score \>3.0~* Hepatic steatosis \>5% wet weight on hepatic proton magnetic resonance spectroscopy (1H-MRS)~* INR \<1.2; Conjugated Bilirubin \<2umol/L and Albumin \>35gm/L~Exclusion Criteria:~* Type 1 or 2 diabetes mellitus~* Treatment with oral hypoglycemic agents~* Ongoing participation in a formal weight loss program or interventional clinical trial~* Panhypopituitarism and genetic causes of obesity i.e. Prader-Willi syndrome~* Alcohol consumption \>20 g/day~* Serum creatinine above normal range for age~* History of previous or predisposition to intestinal obstruction~* Pre-existing gastrointestinal disease i.e. inflammatory bowel disease; celiac disease~* Drugs that influence energy metabolism, intestinal transit, substrate metabolism

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).